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Abstract
The regulation of osteogenesis is important for bone formation and fracture healing. Despite advances in
understanding the molecular mechanisms of osteogenesis, crucial modulators in this process are not well-
characterized. Here we demonstrate that suppression of signal transducer and activator of transcription 5A (STAT5A)
activates distal-less homeobox 5 (DLX5) in human bone marrow-derived stromal cells (hBMSCs) and enhances
osteogenesis in vitro and in vivo. We show that STAT5A negatively regulates expression of Dlx5 in vitro and that
STAT5A deletion results in increased trabecular and cortical bone mass and bone mineral density in mice. Additionally,
STAT5A deletion prevents age-related bone loss. In a murine fracture model, STAT5A deletion was found to
signiﬁcantly enhance bone remodeling by stimulating the formation of a fracture callus. Our ﬁndings indicate that
STAT5A inhibition enhances bone formation by promoting osteogenesis of BMSCs.
Introduction
Human bone marrow mesenchymal stromal cells
(hBMSCs) may differentiate into osteoblasts, chon-
drocytes, adipocytes, or tenocytes depending on culture
conditions. Among these, osteoblast differentiation is
important for increasing bone mass. Osteoblast differ-
entiation of hBMSCs is a well-characterized process and
proceeds as a result of the timely expression of genes,
such as alkaline phosphatase (ALP), runt-related tran-
scription factor 2 (RUNX2), distal-less homeobox 5
(DLX5), osterix (OSX), and osteocalcin (OCN), followed
by extracellular matrix synthesis and mineralization1,2.
RUNX2 has been characterized as the master transcrip-
tion factor in osteogenic differentiation and bone forma-
tion3,4. Another transcription factor, DLX5, is also
expressed in osteoblasts. DLX5 is an important regulator
in the development of mineralized tissues because it
induces expression of RUNX2 in the bone morphogenetic
protein (BMP) signaling pathway5. DLX5 is also involved
in osteoblast maturation6, and Dlx5-/- mice have been
found to have severe craniofacial abnormalities with
delayed ossiﬁcation of the dermatocranial bones7. These
ﬁndings suggest that the Dlx5 gene may play a role in
bone formation and fracture healing.
Members of the signal transducers and activators of
transcription (STAT) family play important roles in cell
proliferation, differentiation, and survival via effects on
the expression of cytokines, growth factors, and hor-
mones8–11. Like other STAT family members, STAT5 was
originally identiﬁed as a cytosolic signaling molecule
involved in proliferation, differentiation, and apoptosis in
cancer cell lines12,13. Following stimulation by various
cytokines, STAT5 becomes phosphorylated and forms a
dimer14,15. The STAT5 dimer then translocates into the
nucleus where it may bind to interferon-γ-activated
sequence (GAS) motifs, promoting the transcription of
target genes9,16,17. There are two isoforms of STAT5:
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STAT5A and STAT5B18. Interestingly, STAT5A and
STAT5B are encoded by separate genes, but the proteins
are 90% identical at the amino acid level14. The distinct
functions of these isoforms have been explored in several
in vivo studies by using STAT5 global knockout mice19.
The prolactin-mediated functions are blocked in the
mammary gland by STAT5A-/-10,20, while STAT5B-/-
disrupts the functions that are regulated by the growth
hormone in the liver11,21. Mostly, the studies about
STAT5 global knockout mice were conducted in hema-
topoietic stem cells20,22,23.
Recently, STAT5 was found to function as a negative
regulator of bone resorption in osteoclasts in vitro and
in vivo24. Another study reported that STAT5–RUNX2
interaction promotes osteoblast differentiation
in vitro25. However, no study has yet distinguished the
roles in osteoblast differentiation played by the different
isoforms of STAT5. Previously, Jung et al. demonstrated
that STAT5A plays a major role in adipogenesis of
hBMSCs and STAT5B performs only a supportive
function in these processes26. These results suggest that
STAT5A plays an essential role in maintaining bone
homeostasis by balancing osteogenesis and adipogen-
esis. In this study, we aimed to characterize the role of
STAT5A in osteoblasts. By clarifying which STAT5
isoform contributes to osteoblast differentiation, our
ﬁndings might identify a novel therapeutic target for
bone diseases.
In this study, we found that STAT5A played an
important role in bone formation and regeneration. We
found that inhibition of STAT5A promoted osteoblast
differentiation and bone formation through the activation
of DLX5 signaling. STAT5A deletion was found to result
in signiﬁcantly decreased bone loss in a murine age-
related osteoporosis model. Moreover, in a murine frac-
ture model, we found that STAT5A deletion enhanced
bone healing by stimulating new bone formation. These
ﬁndings support an inhibitory function for STAT5A in
osteogenesis and suggest therapeutic potential for
STAT5A inhibition in age-related osteoporosis and frac-
ture healing.
Results
Overexpression of STAT5A suppresses osteogenesis in
hBMSCs
To investigate the possible role of STAT5 during
osteogenesis, we ﬁrst examined STAT5 isoform expres-
sion during osteogenesis in hBMSCs. Interestingly,
STAT5A was found to increase in response to induction
of osteogenesis after 6 days (Fig. 1a). However, there was
no change in the expression of STAT5B during osteo-
genesis, while DLX5 and RUNX2, which are key osteo-
genic markers, were decreased in the later stage of
osteogenesis. To examine the effects of STAT5A and
STAT5B on osteogenesis, we overexpressed STAT5A and
STAT5B in hBMSCs. On day 14 after the induction of
osteogenesis, mineralization of STAT5A-overexpressed
hBMSCs was signiﬁcantly decreased compared to that of
control hBMSCs and STAT5B-overexpressed hBMSCs
(Fig. 1b, c). Following Alizarin Red S staining and quan-
tiﬁcation, we also conﬁrmed protein levels for the osteo-
genic marker genes DLX5 and RUNX2. Overexpression of
STAT5A in hBMSCs was found to result in signiﬁcantly
decreased DLX5 expression but not decreased RUNX2
expression. Overexpression of STAT5B, however, had no
effect on these proteins (Fig. 1d, e). Accordingly, STAT5A
decreased messenger RNA (mRNA) levels of DLX5 and its
downstream genes coding for bone sialoprotein (BSP) and
osteopontin (OPN) but the mRNA of RUNX2 was not
changed (Fig. 1f). These ﬁndings suggest that STAT5A
functions during osteogenesis of hBMSCs via regulation
of DLX5 expression.
Suppression of STAT5A promotes osteogenesis in hBMSCs
To clarify the distinct roles of STAT5A and STAT5B in
osteogenesis of hBMSCs, we knocked down STAT5A and
STAT5B using small interfering RNAs (siRNAs), and we
also treated hBMSCs with a STAT5 inhibitor (sc-355979).
Suppression of STAT5A by siRNA had no effect on
mRNA and protein expression of STAT5B (Supplemen-
tary Figures 1a and b). The siRNA-mediated knockdown
of STAT5A promoted osteoblast differentiation, while
siRNA-mediated knockdown of STAT5B had no effect
(Fig. 2a, b). We then tested whether STAT5A regulates
the expression of DLX5. The siRNA-mediated knock-
down of STAT5A increased DLX5 protein expression
(Fig. 2c, d). Consistently, a STAT5 inhibitor-induced
mineral accumulation in a dose-dependent manner at day
14 after the induction of osteogenesis (Fig. 2e). At the
dose for which the STAT5 inhibitor exhibited its maximal
effect (10 μM), mineral accumulation was increased about
2.5-fold over that in vehicle control-treated cells (Fig. 2f).
Accordingly, the STAT5 inhibitor increased DLX5 mRNA
and protein expression in a dose-dependent manner in
hBMSCs (Fig. 2g, h).
STAT5A directly regulates DLX5 in hBMSCs
To examine the relationship between STAT5A and the
osteogenic transcriptional regulator DLX5 luciferase
assays for each regulator were performed at day 5 after
induction of osteogenesis in hBMSCs. STAT5A reduced
DLX5 promoter activity in a dose-dependent manner
(Supplementary Figure 2a). Furthermore, DLX5 promoter
assays showed that the STAT5 inhibitor partially restored
DLX5 promoter activity that had been decreased by
STAT5A (Supplementary Figure 3b).
To characterize the mechanism by which STAT5A
suppresses DLX5 promoter activity, we ﬁrst predicted a
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STAT5A-binding site within the DLX5 promoter region
(Supplementary Figure 3c, asterisk) using the transcrip-
tion element search system (TESS). We then designed
truncated constructs of the DLX5 promoter (Supple-
mentary Figure 3c). We observed signiﬁcantly decreased
DLX5 promoter activity in constructs containing the
STAT5A-binding site relative to vector control, vs. no
change was seen in the activities of constructs without a
STAT5A-binding site (Supplementary Figure 3d). Fur-
thermore, chromatin immuno-precipitation (ChIP) assays
demonstrated that osteogenic stimulation for 5 days
induced recruitment of STAT5A to the DLX5 promoter,
supporting the occurrence of direct regulation of DLX5
expression by STAT5A (Supplementary Figure 3e).
Deletion of STAT5A enhances bone formation in mice
To determine the in vivo role of STAT5A in skeletal
development, we bred mice up to the seventh generation.
Using whole-mount Alizarin Red/Alcian Blue-stained
skeletal preparations, general aspects of skeletal develop-
ment were not found to differ between E19.5 embryos of
wild-type and Stat5a-/- mice (Supplementary Figure S2).
However, postnatal histologic analysis using Masson’s
Trichrome staining revealed that femur trabecular bone
Fig. 1 Suppressed osteoblastic differentiation of hBMSCs by overexpression of STAT5A. a Protein levels of STAT5A, STAT5B, DLX5, and RUNX2
during osteogenesis of hBMSCs. b Alizarin Red S staining demonstrating the effect of STAT5 overexpression on the osteogenesis at day 14. Scale bar,
60 μm. c Quantiﬁcation of Alizarin Red S staining. d Western blot analysis of protein expression of osteogenic master genes, DLX5 and Runx2 after
STAT5 overexpression. GAPDH was used as a control. e Quantiﬁcation of DLX5 and RUNX2 protein levels. f Gene expression of DLX5 and expression
of downstream genes of DLX5 after 4 days with STAT5 overexpression in hBMSCs using real-time PCR. All mRNA and protein levels were normalized
with GAPDH. Each experiment was performed in triplicate (n= 3). All error bars indicate ± SEM. *P < 0.01; **P < 0.01; ***P < 0.001
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mass was markedly increased in Stat5a-/- mice compared
to that in wild-type mice (Fig. 3a). Microcomputed
tomography (μCT) analysis of femurs also showed that
Stat5a deletion resulted in increased trabecular and cor-
tical bone mass relative to wild-type mice (Fig. 3b, c). We
found that multiple μCT parameters for trabecular bone
were increased in Stat5a-/- mice compared to wild-type
mice (Fig. 3d–h). Also, we analyzed the difference
between 10 and 40 weeks in the two genotypes. In
Stat5a-/- mice, the bone mineral density (BMD) reduction
rate between 10 and 40 weeks was lower than that of wild-
type mice. We found that Stat5a deletion reversed age-
related reductions in bone mass and BMD in 40-week-old
mice, suggesting that Stat5a deletion had a protective
effect against age-related osteoporosis. Additionally, cor-
tical thickness, one of the most important factors in
determining mechanical bone strength, was signiﬁcantly
higher in Stat5a-/- mice compared to wild-type mice
(Fig. 3i). Cortical bone volume and cortical cross-sectional
area were also higher in Stat5a-/- mice compared to wild-
type mice (Fig. 3j, k). Femoral shaft biomechanical prop-
erties were assessed by three-point bending, and Stat5a
deletion resulted in signiﬁcantly increased bone strength
during bending compared to wild-type mice (Fig. 3l).
Taken together, our results suggest a role for STAT5A in
the maintenance of bone mass.
STAT5A deletion promotes osteogenesis in mBMSCs
To investigate the osteoblast activity of mouse bone
marrow-derived stromal cells (mBMSCs), we isolated
mBMSCs from wild-type and Stat5a-/- mice. Stat5a-/-
mBMSCs showed signiﬁcantly higher baseline ALP
activity compared to wild-type mice (Fig. 4a, b). Regard-
less of age, mineral accumulations in Stat5a-/- mBMSCs
were markedly higher compared to wild-type mice at day
8 after the induction of osteogenesis (Fig. 4c). Interest-
ingly, mineral accumulations in 30-week-old Stat5a-/-
mBMSCs were decreased compared to 10-week-old
Stat5a-/- mBMSCs, but comparable to those of 10-week-
old wild-type mice (Fig. 4d). Accordingly, DLX5 protein
and mRNA expression levels were higher in Stat5-/-
mBMSCs compared to those in wild-type mice (Fig. 4e, f).
Stat5a deletion led to signiﬁcant increases in mRNA
expression of the osteogenic genes Alp, Bsp, Opn, and Ocn
Fig. 2 Induced osteoblastic differentiation through increased DLX5 expression by inhibition of STAT5A in hBMSCs. a Alizarin Red S staining
to detect suppression of STAT5A and STAT5B on osteogenesis using targeted siRNA. Staining was performed on day 14 of osteogenesis. Scale bar, 30
μm. b Quantiﬁcation of Alizarin Red S staining. c Western blot analysis of DLX5 protein expression after silencing of STAT5A in hBMSCs.
d Quantiﬁcation of DLX5 protein level compared with GAPDH expression level. e Alizarin Red S staining for the effect of STAT5 inhibitor during
osteogenesis of hBMSCs. STAT5 inhibitor (sc-355797) was used at concentrations of 0, 2, 6, and 10 μM. Staining was performed at day 14 of
osteogenesis. Scale bar, 30 μm. f Quantiﬁcation of Alizarin Red S staining. g Analysis of DLX5 mRNA level after 10 μM STAT5 inhibitor treatment.
mRNA level was checked on day 5 of osteogenesis. h Western blot analysis of DLX5 protein expression after STAT5 inhibitor treatment. Protein level
was detected on day 5 of osteogenesis. Each experiment was performed in triplicate (n= 3). All error bars indicate ±SEM. *P < 0.01; **P < 0.01; ***P <
0.001
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(Fig. 4g). Next, we examined whether STAT5A over-
expression reversed DLX5 expression in Stat5a-/-
mBMSCs. STAT5A overexpression in Stat5a-/- mBMSCs
signiﬁcantly decreased Dlx5 mRNA and protein expres-
sion, which had been increased by STAT5A deletion
(Fig. 4h–j). In accordance with these ﬁndings, Stat5a
overexpression decreased mineral accumulation and cal-
ciﬁcation in Stat5a-/- mBMSCs (Fig. 4k, l). Conversely,
DLX5 suppression in Stat5a-/- mBMSCs resulted in
decreased osteogenesis (Supplementary Figure 4). These
results demonstrate that STAT5A control osteogenic
differentiation by regulating of DLX5.
STAT5A deletion promotes bone fracture healing
We next investigated the possible roles of STAT5A in
fracture healing using a murine fracture model. In this
experiment, we generated femur fractures in 6-week-old
wild-type and Stat5a-/- mice as previously described27. At
2 and 4 weeks post-procedure, we then examined callus
formation using μCT (Fig. 5a). Analysis of μCT images
found that callus area in Stat5a-/- mice was increased at
2 weeks post-fracture and decreased at 4 weeks post-
fracture, as compared to wild-type mice (Fig. 5b). Inter-
estingly, the reduction rate of callus bone and cartilagi-
nous callus in Stat5a-/- mice were signiﬁcantly higher than
Fig. 3 Increased bone formation of Stat5a-/- mice. a Masson’s Trichrome staining of longitudinal sections of 10-week-old and 40-week-old male
wild-type (WT) and Stat5a-/- (KO) femurs. Scale bar: 500 μm (top) and 200 μm (bottom) (10-weeks: n= 8 and 40-weeks: n= 6 per each group).
b Representative µCT images of trabecular bone from 10-week-old and 40-week-old male wild-type and Stat5a-/- femurs. Scale bars, 0.5 mm.
c Representative µCT images of cortical bone at 10 and 40 weeks of age in male wild-type and Stat5a-/- femurs. Scale bars, 0.5 mm. d–h Quantitative
µCT analysis of trabecular bone parameters for 10-week-old and 40-week-old male wild-type (WT) and Stat5a-/- (KO) femurs, including (d) bone
volume fraction ratio (BV/TV), (e) volumetric BMD of trabecular bone, (f) trabecular thickness (Tb.Th), (g) trabecular number (Tb.N), and (h) trabecular
separation (Tb.Sp) are shown. (i–k) Quantitative µCT analysis of cortical bone parameters for 10-week-old and 40-week-old male wild-type (WT) and
Stat5a-/- (KO) femurs, with (i) cross-sectional thickness (Cs.Th), (j) bone volume, and (k) cross-sectional area (Cs.Area) are shown. l Maximum load on
femurs from postnatal 10-week-old mice (n= 8 for each group). All error bars indicate ±SEM. *P <0.01; **P < 0.01; ***P < 0.001
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wild-type mice (Fig. 5b, c). Accordingly, cartilaginous
callus stained with Safranin O and total callus stained with
Masson’s Trichrome showed similar patterns to those
found by μCT, suggesting that Stat5a deletion accelerated
the fracture healing process in our model (Fig. 5c–f).
Furthermore, immunohistochemical staining demon-
strated that DLX5 expression was increased at the frac-
ture site of Stat5a-/- mice. Notably, DLX5 was highly
expressed in periosteal bone at the fracture site in
Stat5a-/- mice (Fig. 5g). Overall, these results indicate that
Stat5a deletion promotes bone regeneration and healing
under fracture conditions.
STAT5A deletion increased osteoclastogenesis in vivo
Next, we examined the effect of STAT5A on osteoclast
differentiation in mouse bone marrow monocytes
(mBMMs). mBMMs from wild-type and Stat5a-/- mice
were cultured for 3–4 days in α-minimum essential
medium (α-MEM) with receptor activator of nuclear
factor-kappa B ligand (RANKL) and macrophage colony
stimulating factor (M-CSF). On day 4 after the induction
of osteoclastogenesis, osteoclast differentiation ability was
measured by counting tartrate-resistant acid phosphatase
(TRAP) positive multinucleated osteoclasts (deﬁned as
those with ≥3 nuclei. Stat5a deletion, however, had no
effect on osteoclast differentiation. The numbers of
TRAP-positive multinucleated osteoclasts showed no
difference between Stat5a-/- and wild-type specimens
(Supplementary Figures S5a and b). Next, multinuclear
osteoclasts were identiﬁed in fractured femoral H&E
section28,29. At 2 weeks post-fracture, the number of
multinuclear osteoclasts were higher in Stat5a-/- mice
than wild-type. Intriguingly, at 4 weeks post-fracture, the
multinuclear osteoclasts were lower in Stat5a-/- mice than
wild-type (Supplementary Figures S6a and b). To conﬁrm
these observations, we performed immunohistochemistry
against dendritic cell-speciﬁc transmembrane protein
(DC-STAMP). DC-STAMP has been reported as an
inducer of osteoclastogenesis and core factor for cell–cell
fusion of osteoclast30,31. As a result, at 4 weeks post-
fracture, the DC-STAMP-positive cells were decreased in
Stat5a-/- mice group (Supplementary Figures S6c). These
ﬁnding supported that the smaller callus at 4 weeks in
Stat5a-/- mice suggests a rapid callus remodeling.
Discussion
Emerging evidence suggests that Janus-activated kinase
(JAK)-STAT signaling plays an important role in osteo-
blast differentiation and bone formation27,32,33. Tajima
et al. have reported that inhibition of STAT1 accelerates
osteoblast differentiation and bone fracture healing by
regulation of OSX27, and Levy et al. reported that inhi-
bition of STAT3 results in the augmentation of BMP-
induced osteogenic differentiation32. Furthermore, che-
mical inhibitors of STAT1 and STAT3 have been pro-
posed for the treatment of fractures. Also, as Zhou
suggested, the inactivation of stat3 by mutation in
osteoblast/osteocyte-speciﬁc reduced bone formation34.
Dieudonne et al. showed that STAT5 inhibitor abrogated
in vitro osteogenesis induced by E3 ubiquitin-protein
ligase CBL (c-CBL) silencing in hBMSCs25. They, how-
ever, did not explore the isoform-speciﬁc functions of
STAT5A and STAT5B during osteoblast differentiation.
In the present study, we sought to clarify isoform-speciﬁc
functions of STAT5A and STAT5B and investigate in vivo
role of STAT5 in the bone. Surprisingly, we found that
inhibition of STAT5A signiﬁcantly increased osteoblast
differentiation in hBMSCs, whereas inhibition of STAT5B
showed no effect on osteoblast differentiation (Fig. 2a, b).
Thus, we investigated the relationship between STAT5A
and osteogenic transcriptional factors and in vivo role of
STAT5A for bone formation and fracture healing in
murine models.
One study reported that DLX5 is a central regulator of
bone homeostasis through direct regulation of osteogen-
esis35. Previous studies have reported that DLX5 is
required for RUNX2 expression under BMP
signaling36–38. We found that ALP activity and DLX5
expression in Stat5a-/- mBMSCs were higher than those
in wild-type mice during osteogenic differentiation
(Fig. 4b–f). STAT5A overexpression in Stat5a-/- mBMSCs
was found to decrease DLX5 expression and impair
(see ﬁgure on previous page)
Fig. 4 Induced osteoblast differentiation in Stat5a-/- mBMSCs via upregulation of DLX5. a ALP staining of 10-week-old wild-type and Stat5a-/-
mBMSCs at day 0, as indicated. Scale bar, 60 μm. b Relative ALP activity assay results at days 0 in wild-type and Stat5a-/- mBMSCs. c and d Alizarin Red
S staining (c) and quantitative analysis (d) of at day 8 after induction of osteogenesis in 10-week-old, 20-week-old, and 30-week-old wild-type and
Stat5a-/- mBMSCs. e Protein levels of DLX5 in 10-week-old, 20-week-old, and 30-week-old male wild-type and Stat5a-/- mBMSCs using western
blotting at 5 days after osteogenesis. f mRNA levels of Dlx5 in wild-type and Stat5a-/- mBMSCs at day 3 after the induction of osteogenesis. g mRNA
levels of osteoblast-related genes Alp, Bsp, and Opn at day 3 and mRNA level of Ocn at day 7 after the induction of osteogenesis. h–j Relative mRNA
(h) and protein levels (I and j) of DLX5 depending on exogenously increased Stat5a expression in wild-type and Stat5a-/- mBMSCs. pcDNA-mStat5a
was transfected in Stat5a-/- mBMSCs. mRNA and protein levels of Dlx5 were checked at day 3 and 5 after osteogenesis, respectively. Osteogenesis was
induced after overexpression of Stat5a by transfection. k The osteoblast differentiation of Stat5a-/- mBMSCs upon overexpression of STAT5A using
Alizarin Red S and Von Kossa staining at day 8 after induction of osteogenesis. l Quantiﬁcation of Alizarin Red S staining in Stat5a-/- mBMSCs. Each
experiment was performed in triplicate (n= 3). All error bars indicate ±SEM. *P < 0.01; **P < 0.01; ***P < 0.001
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osteogenic differentiation (Fig. 4). Our results further
indicated that STAT5A inhibits DLX5 expression and
thereby acts as a negative regulator in osteogenesis.
Interestingly, we found seemingly contradictory protein
levels of STAT5A and DLX5 during osteogenesis. Speci-
ﬁcally, expression of STAT5A was found to increase
throughout the process of osteoblast differentiation
(Fig. 1a). This increase in STAT5A seems paradoxical
because of its negative effects on osteogenesis. The reason
for this pattern and its biological signiﬁcance have not
been previously described. An earlier study found that
expression of DLX5 is normally decreased in the late
stages of osteogenesis and disappears in fully matured
bone39. Expression of DLX5 is known to impair the ability
of hBMSCs to proceed to the last stages of osteogenesis
through suppression of osteocalcin, a marker of terminal
Fig. 5 Enhanced bone fracture healing in Stat5a-/- mice. a Representative longitudinal sections of fractured femurs from wild-type and Stat5a-/-
mice at 2 and 4 weeks post-fracture. 6-week-old male mice were used for the fracture model. Scale bar, 4 mm (n= 16 per each group). b Quantitative
analysis of newly formed callus volume at 2 and 4 weeks post-fracture. c–f Representative histological analysis of parafﬁn sections of calluses
from wild-type and Stat5a-/- mice at 2 and 4 weeks post-fracture stained with (c) Safranin O/Fast Green staining for cartilaginous bone callus.
d Quantitative analysis of remaining cartilaginous callus area at 2 and 4 weeks post-fracture (n= 8 per each group). Scale bar, 0.5 mm. e Masson’s
Trichrome staining for total callus. f Quantitative analysis of total callus area at 2 and 4 weeks post-fracture (n= 8 per each group). Scale bar, 0.5 mm.
g Immunohistochemistry against DLX5 at 2 weeks post-fracture of wild-type and Stat5a-/- mice in the fractured femoral section. Scale bars, 100 μm
(n= 5 for each group). All error bars indicate ±SEM. *P <0.01; **P <0.01; ***P <0.001
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osteogenic differentiation6,40,41. Consistent with this pre-
vious report39, our results showed that the expression of
DLX5 decreased as osteogenesis progressed (Fig. 1a).
Taken together, these ﬁndings suggest that the increased
expression of STAT5A during osteogenesis may provide a
homeostatic mechanism that counterbalances the sup-
pressive effects of excessive DLX5 activity during the late
stages of osteogenesis.
In our murine model, the skeletal phenotype of Stat5a-/-
embryos was not found to differ from wild-type controls
(Supplementary Figure S2), but postnatal Stat5a-/- mice
were found to have greater bone mass than postnatal
wild-type mice. The ﬁnding of increased bone mass in
Stat5a-/- mice was maintained with aging. Age-related
bone loss was partially protected against in Stat5a-/- mice,
and the bone mineral densities of 40-week-old Stat5a-/-
mice were comparable to those of young wild-type mice
(Fig. 3d, e). These ﬁndings are consistent with several
previous studies that have reported that DLX5 expression
is related to postnatal bone developments and regulation
of bone homeostasis in adulthood5,42. Our results suggest
that Stat5 deletion affects postnatal bone formation via
regulation of DLX5.
In addition, Stat5 deletion increased not only trabecular
bone density but also cortical bone formation (Fig. 3i–k).
The strength of Stat5a-/- femurs was found to be greater
than that of wild-type mice during biomechanical testing
(Fig. 3l). We hypothesize that increased DLX5 expression
resulting from Stat5 deletion may especially target peri-
osteal bone modeling and lead to the observed increase in
mechanical strength in Stat5a-/- mouse bones compared
to wild-type specimens. This speculation is supported by
our results showing that DLX5 expression predominates
in periosteal bone (Fig. 5g), possibly due to the presence of
greater numbers of osteoblasts at a speciﬁc stage of dif-
ferentiation7,43,44. The balance between bone formation
and bone resorption is essential for bone homeostasis. In
osteoclast differentiation, a DC-STAMP is a crucial factor
in osteoclast fusion. Deletion of STAT5A had no effect on
osteoclast differentiation in vitro, but the increase in
number of osteoclasts and DC-STAMP positive cells in
Stat5a-/- mice had resulted in rapid callus remodeling
(Supplementary Figure 6). Overall, our results demon-
strated that STAT5A deletion promotes osteoblast activ-
ity and that STAT5A plays an important role in regulating
bone formation and bone remodeling.
In conclusion, we have described a novel mechanism of
STAT5A in bone homeostasis through regulation of the
DLX5. In addition, we demonstrated, for the ﬁrst time, the
STAT5A function in hBMSCs during osteogenesis and
conﬁrmed its function in in vivo. Taken all together, our
ﬁndings contribute to understand the mechanism of
STAT5A in controlling bone homeostasis and promoting
fracture healing. Furthermore, this work may offer a new
therapeutic strategy for preventing age-related
osteoporosis.
Materials and methods
Cell culture and differentiation conditions
Selection of hBMSCs was performed by selecting them
according to the cells’ natural tendency to adhere to the
culture dish. Primary hBMSCs were cultured in growth
medium, Dulbecco’s modiﬁed Eagle’s medium-low glucose
(DMEM-LG; Gibco, Carlsbad, CA, USA) with 10% fetal
bovine serum (FBS; Gibco), 1% antibiotic–antimycotic
solution (Invitrogen, Grand Island, NY, USA), and con-
ﬂuence was achieved within 7 days in 5% CO2 at 37 °C. For
osteogenesis, cells were cultured in DMEM-LG with 1 μM
dexamethasone (Sigma, St. Louis, MO, USA), 10mM β-
glycerophosphate (Sigma), and 50 μM ascorbic acid
(Sigma) for 14 days. Mouse bone marrow-derived MSCs
(mBMSCs) were isolated from the femurs and tibias of 3–5
mice between 10 and 30 weeks of age. mBMSCs were
cultured in growth medium with α-MEM (Gibco) with
10% FBS, 1% antibiotic–antimycotic solution, and 2mM L-
glutamine (Invitrogen, Carlsbad, CA, USA) in 5% CO2 at
37 °C45. To induce osteogenic differentiation, cells were
cultured in growth medium with 10mM β-
glycerophosphate and 50 μM ascorbic acid for 8 days.
For osteoclastogenesis, mouse bone marrow monocyte
cells (mBMMs) were cultured for 3–4 days in α-MEM
containing 15 ng/ml mRANKL (R&D systems, MN, USA)
and 40 ng/ml mMCSF (R&D systems)46.
Plasmid constructs
Recombinant pcDNA-mStat5a and pcDNA-mStat5b
plasmids were kindly gifted by Dr. Hiroko Yamashita
(Nagoya City University, Nagoya, Japan). pcDNA-
hSTAT5A, pcDNA-hSTAT5B, and pcDNA-hDLX5 were
constructed by amplifying each coding region from cDNA
of HeLa cells. All promoter vectors were obtained with
polymerase chain reaction (PCR) of human genomic
DNA. Human DLX5 and STAT5A promoter regions
spanning −2208/+142 base pairs (bp) and −2121/+88 bp
were inserted into a pGL3 basic vector (Addgene, Cam-
bridge, MA, USA) and named pGL-DLX5 Full and pGL-
STAT5A, respectively. pGL-DLX5 Del1–pGL-DLX5
Del4, containing 5′ serial deletions fragments of the DLX5
promoter were cloned by amplifying the regions from
−2003 to +142, −1751 to +142, −1254 to +142, and
−645 to +142 bp, respectively.
Gene transfection and luciferase reporter assays
Recombinant plasmids were transfected into hBMSCs
using Lipofectamine LTX and Plus Reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
protocol. The medium was then replaced with 2 ml
DMEM-LG with 10% FBS and 1% antibiotic–antimycotic
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solution or osteogenic medium. After 24 h, the cells were
lysed with 200 µl of 1 × passive lysis buffer (Promega,
Madison, WI, USA) per tube, and cell debris was
removed. Luciferase activity was measured using the
Dual-Luciferase Reporter Assay Kit (Promega, Madison,
WI, USA). Relative luciferase activity was normalized by
renilla activities to adjust for transfection efﬁciency.
Inhibition of STAT5A and STAT5B
Synthetic siRNAs for STAT5A, STAT5B, and DLX5
mRNA were purchased from Bioneer (Bioneer, Daejeon,
South Korea). 80% conﬂuence hBMSCs were transfected
with each siRNA using Lipofectamine LTX (Invitrogen).
The cells were then collected and prepared for analysis.
The silencing effects of siSTAT5A and siSTAT5B were
checked by measuring reduced protein expression of
STAT5A and STAT5B. Negative control duplexes (Bio-
neer, Korea) were used as negative controls. A STAT5
inhibitor which inhibits phosphorylation of STAT5 via
binding to the SH2 domain of STAT5 was purchased
from Santa Cruz Biotechnology (sc-355979, Dallas, TX,
USA).
Isolation of mRNA and real-time (RT)-PCR analysis
Total RNA was isolated using the RNeasy Mini Kit
(Qiagen, Venlo, Netherlands) according to the manu-
facturer’s protocol. For quantitative RT-PCR, com-
plementary DNA (cDNA) was synthesized by oligo dT18
primer (Invitrogen) using the isolated RNA as a template.
The Omniscript Reverse-Transcription Kit (Qiagen) was
used to synthesize the cDNA, according to the manu-
facturer’s instructions. RT-PCR was then performed using
2× qPCRBIO SyGreen Mix Hi-Rox (PCR Biosystems,
London, UK) and analyzed using the Applied Biosystems
(ABI) StepOne Plus System (ABI, Carlsbad, CA, USA). All
primers were purchased from Bioneer. The relative
expression of each gene was normalized by GAPDH
expression. The speciﬁc primer pairs are shown in Sup-
plementary Table S1. All reactions were performed in
triplicate.
Western blot analysis and antibodies
Collected cells were washed twice with 1× phosphate
buffered saline (PBS) and lysed by the addition of 100 µl of
whole cell lysis buffer (60 mM Tris–HCl pH 6.8, 1% SDS)
for 10 min at 100 °C. Collected supernatants, following
centrifugation at 13,000 rotations/min (rpm) for 10min,
were quantiﬁed using a BCA Protein Assay Kit (Thermo
Scientiﬁc, Rockford, IL, USA). For western blot analysis,
25 µg of protein were separated on 10% SDS–PAGE
under reducing conditions. Subsequently, proteins were
transferred onto polyvinylidene diﬂuoride (PVDF)
membranes (Amersham Pharmacia, Piscataway, NJ, USA)
in transfer buffer (1.4% glycine, 20% methanol and 25mM
Tris–HCl, pH 8.3 for 90min at 70 V). After that, mem-
branes were incubated in blocking solution (1× TBST (50
mM Tris–HCl, 150mM NaCl, and 0.1% Tween-20)
containing 5% skimmed milk powder) for 1 h at room
temperature. Then blocked membranes were incubated in
1% skimmed milk powder solution including primary
antibodies overnight at 4 °C. Membranes were then
washed three times with 1× TBST, followed by incubation
with secondary antibodies for 1 h at room temperature.
Primary antibodies used for blotting were anti-STAT5
(1:1000, Abcam; ab68465), anti-STAT5A (1:1000, Abcam;
ab32043), anti-STAT5B (1:1000, Abcam; ab178941), anti-
DLX5 (1:500, Abcam; ab109737), and anti-RUNX2
(1:1000, Millipore; 05–1478). All secondary antibody
complexes were visualized by autoradiography using ECL
Plus and ECL Western Blotting Detection Systems
(Amersham BioSciences, Buckinghamshire, UK). Signal
quantiﬁcation was performed by scanning the auto-
radiographs. Signal intensities were determined by den-
sitometry analysis using Image J software.
Chromatin immunoprecipitation (ChIP) analysis
ChIP analysis was performed using a ChIP Assay Kit
(Upstate Biotechnology, Charlottesville, VA) according to
the manufacturer’s instructions. Brieﬂy, hBMSCs were
induced to form osteoblasts for 3 days and the differ-
entiated cells were then cross-linked by the addition of 1%
formaldehyde solution for 10min at room temperature.
The cross-linked cells were lysed with SDS lysis buffer and
sonicated. DNA–protein complexes were bound using
antibodies against STAT5A (1:1000, Abcam; ab32043) or
an unspeciﬁc rabbit IgG (1:1000, Santa Cruze; sc2027),
and these immune complexes were collected by binding
with protein A-agarose after an overnight incubation at
4 °C. After the complexes were washed with 1× PBS, DNA
was extracted using phenol/chloroform alcohol pre-
cipitation and used as a template for ampliﬁcation of the
DNA fragments. The speciﬁc primer pairs for the DLX5
promoter are shown in Supplemental Table 2.
ALP staining and activity
Differentiated cells were ﬁxed in a mixture of citrate
working solution (Sigma Aldrich, 854c) and acetone (2:3)
for 30 s and washed in distilled water for 1 min. ALP
staining was performed using a Fast Violet B Salt Kit
(Sigma Aldrich, 815). Cells were placed in ALP staining
solution for 30min and then washed two times with
distilled water. ALP activity was measured using a col-
orimetric assay at day 0. For this assay, cells were washed
two times with ice-cold PBS and harvested in 0.5 ml
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50mM Tris–HCl, pH 7.6. After sonication and cen-
trifugation for 15min at 12,000 rpm, ALP activity of the
supernatant was measured by the quantity of p-nitro-
phenylphosphate released/min/µg total protein using a
microplate reader (VersaMax™ Microplate Leader, CA,
USA) at 405 nm. Total cellular protein amount was
determined using the BCA Assay Kit.
Von kossa staining and Alizarin Red S staining
Differentiated cells were washed twice with PBS and
ﬁxed in a mixture of acetone and methanol (1:1) or 70%
ethanol for Von Kossa staining or Alizarin Red S staining,
respectively. After ﬁxation, cells were washed two times
with distilled water and then stained with either 3% silver
nitrate solution or 2% Alizarin Red S solution for 30min,
respectively. For quantiﬁcation of Alizarin Red S staining,
the stained samples were distained by 10% (weight/
volume) cetylpyridinium chloride for 30min at room
temperature, and then the supernatants were measured
using a microplate reader (VersaMax™ Microplate Leader)
at 595 nm.
Mice
Stat5a general knockout mice10 were gifted from
Dr. Lothar Hennighausen (National Institutes of Health,
MD, USA). Deletion of the Stat5a gene was conﬁrmed by
PCR around the substituted neomycin gene site using the
speciﬁc primer. The study population of Stat5a-/- mice
was generated by intercrossing Stat5a heterozygous
knockout (Stat5a+/-) mice. 10, 20, 30, and 40 weeks old
male mice were used in this study.
μCT analysis
For μCT imaging, soft tissue was dissected from mouse
femurs and the bones were ﬁxed in 70% ethanol for 24 h
at room temperature. The ﬁxed femurs were then ana-
lyzed using high-resolution μCT (Skyscan-1076, Skyscan,
Kontich, Belgium). Image reconstruction and analysis was
then performed using reconstruction software NRecon
(version 1.6.6.0, Skyscan) and CT-analyzer software
CTAn (version 1.13.2.1, Skyscan), respectively. Measured
parameters for epiphyseal trabecular bone were analyzed
using three-dimensional (3D) model visualization soft-
ware CT-Vol (version 2.0, Skyscan). The acquisition set-
ting conditions were followed by an X-ray source voltage
of 70 kVp and a current 140 μA. Beam hardening reduc-
tion depended on a 0.5 mm-thick aluminum ﬁlter. The
pixel size was 18 μm: exposure time was 14.7 s; the rota-
tion step was 0.5°; and full rotation occurred over 360°.
The quantitative analysis for the trabecular parameters
and cortical parameter were measured at the femoral
metaphysis (a total of 300 slices) and femoral diaphysis (a
total of 100 slices), respectively. The measured 3D bone
parameters of 10-week-old mice included the following:
total tissue volume (TV), which included volume mea-
surement of both trabecular and cortical bone; trabecular
bone volume per tissue volume (BV/TV); trabecular
number (Tb. N); trabecular thickness (Tb. Th); trabecular
separation (Tb. Sp); BMD; cortical bone volume (bone
volume); cortical cross-sectional thickness (Cs. Th); and
cortical cross-sectional area (Cs. area).
Murine fracture model
A standardized mid-diaphyseal fracture was induced in
24 wild-type mice and 24 Stat5a-/- mice at 6 weeks of age.
Mice were anesthetized with Zoletil® (30 mg/kg body
weight, Virbac, Carros, France) and Rompun® (10 mg/kg
body weight, Bayer Ontario, Canada), administered by
intraperitoneal injection. The right hind leg was shaved
and disinfected. The femur was then exposed through
lateral incision, and severed in the mid-diaphysis using a
scalpel. The fractured femur was then ﬁxed using 22-
gauge needle. After ﬁxation the surgical wound was irri-
gated with normal saline and closed by nylon suture.
Immediately after fracture creation, post-surgical condi-
tion of the femur was measured using µCT. Mice were
then sacriﬁced at 2 and 4 weeks post-procedure (n= 16
and n= 32 per time point, respectively). There were no
complications or animal deaths during surgery or post-
operative management. At 2 and 4 weeks post-procedure
(n= 8 from the Stat5a-/- group and n= 8 from the wild-
type group per time point) were used for BMD mea-
surements and µCT analysis of callus formation and
mineralization. The other subjects (n= 8 in each group)
were used for mechanical testing at 4 weeks post-
procedure. Calciﬁed callus volume was determined by
subtracting cortical bone volume from the total volume.
Before mechanical analysis and imaging, femurs were
dissected out from the soft tissue and intramedullary pins
were removed. The fracture model protocol was approved
by the Committee on the Ethics of Animal Experiments.
Histology and immunohistochemistry
The fractured femurs were removed from eight mice in
each group and ﬁxed in 10% formalin solution for
5–7 days at room temperature. Femurs were decalciﬁed in
Calci-Clear RapidTM (National Diagnostics Inc., GA,
USA) solution for 3 days at room temperature. Decalciﬁed
femurs were then embedded in parafﬁn blocks. The par-
afﬁn sections were dehydrated by passage through an
ethanol series, cleared twice in xylene, and embedded in
parafﬁn, after which 5mm sections were cut using a
rotary microtome. Decalciﬁed femoral sections were
stained with Masson’s Trichrome, Safranin O, and Fast
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Green. For immunohistochemistry, antigen retrieval was
performed using pH 6.0 citrate buffer for the depar-
afﬁnized sections. Sections were blocked with 5% normal
goat serum, without PBS and without 0.1% Tween 20 for
1 h at room temperature. Sections were then incubated
with DLX5 antibody (1:100, EPR4488, Abcam) and anti-
DC-STAMP (1:100, Millipore; MABF39) for 1 h at room
temperature and with anti-rabbit and anti-mouse sec-
ondary antibodies for 1 h at room temperature. Then the
DAB Substrate Kit (ab64238, Abcam) was used for
detection of DLX5 and DC-STAMP positive cells on tis-
sue sections.
Statistical analysis
The numbers of mice used for in vivo experiments were
based on our pilot experiments and µCT analysis was
performed in a blinded fashion. For checking the normal
distributions of the groups, we ﬁrst performed normality
testing using the Shapiro–Wilk method. If normality tests
were passed, two-tailed, unpaired Student’s t-tests were
used for the comparisons between two groups. If nor-
mality tests were failed, Mann–Whitney tests were used
for the comparisons between two groups. For compar-
isons between three or four groups, we used one-way
ANOVA if normality tests were passed, followed by
Tukey’s post hoc test for all pairs of groups. If normality
tests were failed, Kruskal–Wallis testing was performed
and followed with Dunn’s post hoc test. GraphPad PRISM
Software (version 5.0) was used for statistical analysis. P <
0.05 was considered statistically signiﬁcant. *P < 0.05, **P
< 0.01, ***P < 0.001. All experiments were performed in
biological triplicate.
Study approval
hBMSCs were obtained from the posterior iliac crest of
10 adult donors (age range: 21–51 years) after receiving
approval from the Institutional Review Board. All
experiments with mice were performed in an Animal Care
Center and in accordance with Association for Assess-
ment and Accreditation of Laboratory Animal Care
(AAALAC) International Guidelines. All animal care and
use protocols were approved by the Committee on the
Ethics of Animal Experiments.
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